+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Alzheimer's Disease Drugs Market Research Report by Drug Class, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 4905145
  • Report
  • July 2021
  • Region: Global
  • 192 pages
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The Global Alzheimer's Disease Drugs Market will Grow to USD 5,742.57 Million by 2026, at a CAGR of 9.91%

FEATURED COMPANIES

  • AB Science
  • Amgen Inc.
  • AZ Therapies, Inc
  • Cortexyme
  • GE Healthcare
  • H. Lundbeck A/S
  • MORE
The Global Alzheimer's Disease Drugs Market size was estimated at USD 3,256.48 Million in 2020 and expected to reach USD 3,568.36 Million in 2021, at a Compound Annual Growth Rate (CAGR) 9.91% to reach USD 5,742.57 Million by 2026.



Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Alzheimer's Disease Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug Class, the Alzheimer's Disease Drugs Market was examined across Cholinergic, Combined Drug, and Memantine.
  • Based on Distribution Channel, the Alzheimer's Disease Drugs Market was examined across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Geography, the Alzheimer's Disease Drugs Market was examined across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas was further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific was further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa was further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. This ongoing research amplifies this research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Alzheimer's Disease Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Alzheimer's Disease Drugs Market, including AB Science, AbbVie, Inc, AC Immune SA, Amgen Inc., Amneal Pharmaceuticals, Avanir Pharmaceuticals Inc., Axsome Therapeutics, Inc., AZ Therapies, Inc, BioArctic Neuroscience, Biogen, Inc, Biohaven Pharmaceuticals, Inc, Cortexyme, Eli Lilly and Company, F. Hoffmann-La Roche AG, GE Healthcare, Genentech, Inc., Green Valley Pharmaceuticals, Grifols, S.A., H. Lundbeck A/S, Janssen Pharmaceutica, Lupin Limited, Merz Holding GmbH & Co KG, Mylan N.V., Novartis AG, Otsuka Pharmaceutical Co., Ltd, Pfizer Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., The Takeda Pharmaceutical Company Limited, and vTv Therapeutics Inc.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Alzheimer's Disease Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Alzheimer's Disease Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Alzheimer's Disease Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Alzheimer's Disease Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Alzheimer's Disease Drugs Market?
6. What is the market share of the leading vendors in the Global Alzheimer's Disease Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Alzheimer's Disease Drugs Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AB Science
  • Amgen Inc.
  • AZ Therapies, Inc
  • Cortexyme
  • GE Healthcare
  • H. Lundbeck A/S
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Drug Class Outlook
3.4. Distribution Channel Outlook
3.5. Geography Outlook
3.6. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidences of neurological disorder
5.1.1.2. Rising awareness regarding Alzheimer’s treatment
5.1.1.3. Availability of cost-effective medicine for the treatment of Alzheimer
5.1.2. Restraints
5.1.2.1. High cost of R&D activities for drug development
5.1.3. Opportunities
5.1.3.1. Advances in the treatment of Alzheimer's diseases
5.1.3.2. Adoption of online pharmacies and advantages offered by online channels
5.1.4. Challenges
5.1.4.1. Side effect associated with Alzheimer’s drugs
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry

6. Alzheimer's Disease Drugs Market, by Drug Class
6.1. Introduction
6.2. Cholinergic
6.3. Combined Drug
6.4. Memantine

7. Alzheimer's Disease Drugs Market, by Distribution Channel
7.1. Introduction
7.2. Hospital Pharmacy
7.3. Online Pharmacy
7.4. Retail Pharmacy

8. Americas Alzheimer's Disease Drugs Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Alzheimer's Disease Drugs Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Thailand

10. Europe, Middle East & Africa Alzheimer's Disease Drugs Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. AB Science
12.2. AbbVie, Inc
12.3. AC Immune SA
12.4. Amgen Inc.
12.5. Amneal Pharmaceuticals
12.6. Avanir Pharmaceuticals Inc.
12.7. Axsome Therapeutics, Inc.
12.8. AZ Therapies, Inc
12.9. BioArctic Neuroscience
12.10. Biogen, Inc
12.11. Biohaven Pharmaceuticals, Inc
12.12. Cortexyme
12.13. Eli Lilly and Company
12.14. F. Hoffmann-La Roche AG
12.15. GE Healthcare
12.16. Genentech, Inc.
12.17. Green Valley Pharmaceuticals
12.18. Grifols, S.A.
12.19. H. Lundbeck A/S
12.20. Janssen Pharmaceutica
12.21. Lupin Limited
12.22. Merz Holding GmbH & Co KG
12.23. Mylan N.V.
12.24. Novartis AG
12.25. Otsuka Pharmaceutical Co., Ltd
12.26. Pfizer Inc.
12.27. Sun Pharmaceutical Industries Limited
12.28. Teva Pharmaceutical Industries Ltd.
12.29. The Takeda Pharmaceutical Company Limited
12.30. vTv Therapeutics Inc

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2020 VS 2026 (USD MILLION)
FIGURE 2. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2020 (USD MILLION)
FIGURE 3. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2020 (USD MILLION)
FIGURE 4. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
FIGURE 5. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 6. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET: MARKET DYNAMICS
FIGURE 7. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 8. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2020 VS 2026 (%)
FIGURE 9. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2020 VS 2026 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2026
FIGURE 11. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CHOLINERGIC, 2018-2026 (USD MILLION)
FIGURE 12. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CHOLINERGIC, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 13. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COMBINED DRUG, 2018-2026 (USD MILLION)
FIGURE 14. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COMBINED DRUG, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 15. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MEMANTINE, 2018-2026 (USD MILLION)
FIGURE 16. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MEMANTINE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 17. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2020 VS 2026 (%)
FIGURE 18. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2020 VS 2026 (USD MILLION)
FIGURE 19. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2026
FIGURE 20. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2026 (USD MILLION)
FIGURE 21. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 22. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2026 (USD MILLION)
FIGURE 23. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 24. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2026 (USD MILLION)
FIGURE 25. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 26. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 27. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 28. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 29. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 30. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 31. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 32. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 33. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 34. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 35. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 36. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 37. AUSTRALIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 38. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 39. INDIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 40. INDONESIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 41. JAPAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 42. MALAYSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 43. PHILIPPINES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 44. SINGAPORE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 45. SOUTH KOREA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 46. THAILAND ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 47. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 48. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 49. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 50. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 51. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 52. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 53. NETHERLANDS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 54. QATAR ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 55. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 56. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 57. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 58. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 59. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 60. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 61. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET: FPNV POSITIONING MATRIX
FIGURE 62. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 63. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET, BY TYPE

List of Tables
TABLE 1. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 4. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 5. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CHOLINERGIC, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 6. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COMBINED DRUG, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 7. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MEMANTINE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 8. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 9. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 10. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 11. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 12. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 13. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 14. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 15. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 16. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 17. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 18. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 19. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 20. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 21. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 22. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 23. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 24. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 25. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 26. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 27. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 28. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 29. AUSTRALIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 30. AUSTRALIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 31. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 32. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 33. INDIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 34. INDIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 35. INDONESIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 36. INDONESIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 37. JAPAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 38. JAPAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 39. MALAYSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 40. MALAYSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 41. PHILIPPINES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 42. PHILIPPINES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 43. SINGAPORE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 44. SINGAPORE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 45. SOUTH KOREA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 46. SOUTH KOREA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 47. THAILAND ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 48. THAILAND ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 49. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 50. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 51. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 52. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 53. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 54. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 55. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 56. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 57. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 58. NETHERLANDS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 59. NETHERLANDS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 60. QATAR ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 61. QATAR ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 62. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 63. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 64. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 65. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 66. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 67. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 68. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 69. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 70. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 71. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 72. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 73. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
TABLE 74. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET: SCORES
TABLE 75. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET: BUSINESS STRATEGY
TABLE 76. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET: PRODUCT SATISFACTION
TABLE 77. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET: RANKING
TABLE 78. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 79. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET: MERGER & ACQUISITION
TABLE 80. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 81. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 82. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET: INVESTMENT & FUNDING
TABLE 83. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 84. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • AB Science
  • AbbVie, Inc
  • AC Immune SA
  • Amgen Inc.
  • Amneal Pharmaceuticals
  • Avanir Pharmaceuticals Inc.
  • Axsome Therapeutics, Inc.
  • AZ Therapies, Inc
  • BioArctic Neuroscience
  • Biogen, Inc
  • Biohaven Pharmaceuticals, Inc
  • Cortexyme
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GE Healthcare
  • Genentech, Inc.
  • Green Valley Pharmaceuticals
  • Grifols, S.A.
  • H. Lundbeck A/S
  • Janssen Pharmaceutica
  • Lupin Limited
  • Merz Holding GmbH & Co KG
  • Mylan N.V.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • The Takeda Pharmaceutical Company Limited
  • vTv Therapeutics Inc
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll